"Paxclue Shows Over 95% Symptom Improvement in Elderly GERD Patients"
Interim Results of Post-Marketing Surveillance Published in International Journal
95.32% Symptom Improvement Among Patients Aged 65 and Older
Safety Evaluated in Patients with Comorbidities and Those on Multiple Medications
A recent study has found that Daewoong Pharmaceutical's gastroesophageal reflux disease (GERD) treatment 'Paxclue' (ingredient: fexuprazan hydrochloride) demonstrated effectiveness in symptom improvement and safety even in real-world clinical settings, including among elderly patients.
On July 3, Daewoong Pharmaceutical announced interim results from the post-marketing surveillance (PMS) for Paxclue, revealing that symptom improvement was confirmed in 95.75% of all patients. The findings were published in 'Gut and Liver,' an SCIE-level international journal in the field of gastroenterology.
Unlike strictly controlled clinical trials, this study included elderly patients, patients with comorbidities, and those taking multiple medications, reflecting real-world clinical scenarios. Of the 630 study participants, 46.7% were aged 65 or older, and 14% were 75 or older. Additionally, 71.1% of all patients had comorbid conditions, and 78.6% were taking other medications concurrently.
The research team administered Paxclue 40mg for between 4 and 8 weeks and monitored patient progress, finding that symptoms improved in 95.75% of all patients. In the subgroup of elderly patients aged 65 or older, the symptom improvement rate was 95.32%, similar to the overall patient group.
The quality of life index (GERD-HRQL) improved significantly, dropping from an average of 13.3 points before treatment to 3.0 points after treatment. A lower score on this index indicates less discomfort due to symptoms.
No serious adverse drug reactions were reported in terms of safety. The overall incidence of adverse drug reactions was 2.38%. The company explained that even among patients with hepatic impairment, Paxclue showed consistent efficacy without any drug-related adverse reactions.
Lead researcher Park Muin, professor of gastroenterology at Kosin University Gospel Hospital, commented, "It is significant that we have established clinical evidence supporting the safe and reliable use of this medication, particularly for elderly patients or those with impaired liver function who require special attention in prescribing."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Park Hyungcheol, Head of ETC Marketing Division at Daewoong Pharmaceutical, stated, "This interim PMS analysis demonstrates that Paxclue provides excellent efficacy and high safety even in complex real-world prescribing environments. We will continue to strengthen our medical evidence and enhance our product's competitiveness through ongoing research."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.